Alta Partners Mergers and Acquisitions Summary

Private Equity Profile

Alta Partners’ most common sectors for investment are life science (84%) and medical products (12%). The Firm’s most common investment types include venture (80%) and pipe (9%). In total, Alta Partners has invested in 8 US states and 7 different countries. Its largest (disclosed) acquisition occurred in 2000 when it acquired Cytokinetics for $55M.

In the last 3 years, Alta Partners has exited 2 companies. The Firm’s most common exit type is trade sale (62%). Alta Partners’ largest (disclosed) exit occurred in 2019 when it sold Ellie Mae for $3.7B.

Join Mergr to view Alta Partners’ full profile and discover more large private equity firms just like it.

M&A Summary

  • M&A Total Activity132
    • M&A Buy Activity59
    • M&A Sell Activity73
  • Total Sectors Invested 5
  • Total Countries Invested 7
  • M&A Buy/Sell Connections 68

Alta Partners

1 Embarcadero Center, Suite 3700,
San Francisco, California 94111
United States
(415) 362-4022
www.altapartners.com
alta@altapartners.com

Alta Partners is a venture capital firm that targets investments in early and later stage life science companies, including biopharmaceuticals, medical technology, and information technology businesses. Alta was formed as an early stage investor but has since expanded its investment range to provide later stage growth capital to private and young public companies. Alta was established in 1996 and is headquartered in San Francisco, California.


Investment Criteria

Sectors of Interest: Healthcare Services, Information Technology, Insurance, Life Science, Medical Products, Technology Hardware

Target Transaction Types: Growth Capital, Venture

Geographic Preferences: East US, Midwest US, South US, West US, United Kingdom, Western Europe, Eastern Europe, Scandinavia

Transaction Criteria Min Max
Target Revenue - -
Target EBITDA - -
Investment Size - -
Enterprise Value - -

M&A Summary

Buy vs Sell

Year ≤ '15 '16 '17 '18 '19 '20 T
Buy (0.0/yr) # 59 - - - - - 59
vol $449M $449M
Sell (0.6/yr) # 70 - 2 - 1 - 73
vol $10.6B $3.7B $14.3B
  132

Most Recent M&A

Company Date Value Type
Ellie Mae, Inc. 2019-02-12 3.7B USD Secondary Buyout
Pleasanton, California · www.elliemae.com
DiscoveRx Corp. 2017-07-31 - Add-on Acquisition
Fremont, California · www.discoverx.com
Threshold Pharmaceuticals, Inc. 2017-03-17 - Merger
South San Francisco, California · www.thresholdpharm.com
ZS Pharma, Inc. 2015-11-05 2.7B USD Add-on Acquisition
Coppell, Texas · www.zspharma.com
Kiadis Pharma BV 2015-06-01 - IPO
Amsterdam, Netherlands · www.kiadis.com
aTyr Pharma, Inc. 2015-04-06 - IPO
San Diego, California · www.atyrpharma.com
PneumRx, Inc. 2014-12-04 475M USD Add-on Acquisition
Mountain View, California · www.pneumrx.com
Immune Design Corp. 2014-07-24 - IPO
Seattle, Washington · www.immunedesign.com
Kite Pharma, Inc. 2014-06-20 - IPO
Santa Monica, California · www.kitepharma.com
Zafgen, Inc. 2014-06-18 - IPO
Boston, Massachusetts · www.zafgen.com
View All >>

Portfolio M&A

Company Acquired Add-On/Sale Date #
Bioventus LLC 2012-05-07 BioStructures LLC 2015-11-30 2
Durham, North Carolina · www.bioventusglobal.com Durham, North Carolina · www.bioventusglobal.com
Bioventus LLC 2012-05-07 Advanced Biologics, LLC - OsteoAMP Product Line 2014-10-13 1
Durham, North Carolina · www.bioventusglobal.com , United States

M&A by Sector

Sector Current # Value All-time # Value
Life Science 17 (81%) 275M (99%) 49 (83%) 376M (97%)
Medical Products 3 (14%) 2M (1%) 7 (12%) 13M (3%)
Semiconductors - - 1 (2%) -
Software - - 1 (2%) -
Technology Hardware 1 (5%) - 1 (2%) -
Total 21 $277M 59 $389M

Acquisitions By Geo

State/Country Current # Value All-time # Value
United States 19 (90%) 261M (85%) 50 (85%) 356M (85%)
  California 13 (62%) 127M (41%) 35 (59%) 200M (48%)
  Massachusetts - - 6 (10%) 23M (5%)
  Pennsylvania 2 (10%) 67M (22%) 2 (3%) 67M (16%)
  Maryland 2 (10%) 30M (10%) 2 (3%) 30M (7%)
  Texas - - 2 (3%) -
  Florida 1 (5%) 38M (12%) 1 (2%) 38M (9%)
  North Carolina 1 (5%) - 1 (2%) -
  Washington - - 1 (2%) -
Denmark 1 (5%) 15M (5%) 2 (3%) 32M (8%)
France 1 (5%) 31M (10%) 2 (3%) 31M (7%)
Sweden - - 2 (3%) -
United Kingdom - - 1 (2%) -
Belgium - - 1 (2%) -
Netherlands - - 1 (2%) -
Domestic 19 (90%) 261M (85%) 50 (85%) 356M (85%)
Cross-border 2 (10%) 46M (15%) 9 (15%) 63M (15%)
Total 21 $307M 59 $419M

Acquisitions by Deal Type

Type Current # Value All-time # Value
Venture 18 (86%) 277M (100%) 47 (80%) 389M (100%)
PIPE 1 (5%) - 5 (8%) -
Buyout (LBO, MBO, MBI) 1 (5%) - 4 (7%) -
Growth Capital - - 2 (3%) -
Divestiture 1 (5%) - 1 (2%) -
Total 21 $277M 59 $389M

Exits by Deal Type

Type Total # Value
Trade Sale - Public Company 39 (53%) 8.5B (61%)
IPO 25 (34%) -
Trade Sale 6 (8%) 1.8B (13%)
Secondary Sale 1 (1%) 3.7B (26%)
Bankruptcy 1 (1%) -
Merger 1 (1%) -
Total 73 $14.0B

Deal Values

buy # Total
< $100M 17 $449M
TOTAL $449M
Largest Cytokinetics, Inc.
$55M (2000-11-27)
sell # Total
> $1B 3 $7.4B
$100M to $1B 18 $6.8B
< $100M 2 $97M
TOTAL $14.3B
Largest Ellie Mae, Inc.
$3.7B (2019-02-12)

M&A Connections

Deals %
Acquired from
Strategic(s)
100%
1 100%
Exited to
PE Firm(s)
2%
1 2%
Strategic(s)
98%
46 98%

Investor Summary

Size

Large

PE Assets

2.0B USD

Established

1996

Specialist/Generalist

Specialist

Leadership

Dan Janney

Co-Founder & Managing Director

Pete Hudson

Managing Director

Bob More

Managing Director

Larry Randall

CFO

 Subscribe to unlock this and 152,087
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
1 Week Free Trial Learn More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.9K Private Equity Firms
  • 140K M&A Transactions
  • 148K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.1K M&A Advisors
    (Investment Banks and Law Firms)
  • 41K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Mergr

Product

Company

Legal